Christopher R. Cline - 02 Sep 2026 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: TVTX
Reported as of: 02 Sep 2026
Net transaction value: -$42,610
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:05:20 UTC
Prior SEC filing: 06 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Christopher R. Cline filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 03 Sep 2026.

Key facts

This page summarizes Christopher R. Cline's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 16:05.

Change

Previous filing in this sequence was filed on 06 May 2026.
Current net transaction value: -$42,610.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001943192 Primary reporting owner

Cline Christopher R.

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Sale

Transaction value: $42,610
Shares: -642
Change %: -0.54%
Price: $66.37
Shares after: 118,016
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.